Cervical cancer screening and treatment are neglected in low- and middle-income countries

While there have been substantial improvements in mortality rates and an increase in access to reproductive health interventions in low- and middle-income countries (LMICs), the global health community is neglecting prevention, screening, and treatment for cervical cancer in LMICs. These are the conclusions of a new article in PLOS Medicine this week by Ruby Singhrao and colleagues from the University of California San Francisco, San Francisco.

Using a framework including equity and socio-economic, gender, public health, and health services dimensions, the authors propose four arguments for why screening and treatment should be included as part of the "post-2015 development agenda," for improving reproductive and maternal health outcomes. They argue that the burden of cervical cancer falls on women of reproductive age and that cervical cancer is associated with reduced reproductive capacity. Furthermore, cervical cancer screening and treatment can be integrated into other health services and recent evidence demonstrates that HPV vaccination can protect girls from pre-.

"For cervical cancer, we fortunately now have a wide range of feasible, affordable, and effective prevention options, which make dramatic global reductions in cervical cancer incidence a realistic goal in our lifetime", conclude the authors.

More information: Singhrao R, Huchko M, Yamey G (2013) Reproductive and Maternal Health in the Post 2015 Era: Cervical Cancer Must Be a Priority. PLoS Med 10(8): e1001499. DOI: 10.1371/journal.pmed.1001499

add to favorites email to friend print save as pdf

Related Stories

Too many Pap tests

Jul 26, 2013

Most Australian women are currently having more Pap smears than their health requires, according to new research led by a University of New South Wales academic.

HPV testing could cut cervical cancers by a third

Jun 14, 2013

(Medical Xpress)—Testing women for the human papillomavirus (HPV) first, instead of using the traditional cervical screening test to detect abnormal cells in the cervix, could prevent around 600 cases of ...

Recommended for you

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

11 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Cancer exosome 'micro factories' aid in cancer progression

15 hours ago

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

User comments